AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04074720 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Rectal Swab
Description: optional rectal swab may be collected on day of standard of care procedure
Study NCT02102646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptorelin
Description: Androgen deprivation therapy by Pamorelin 22,5mg/24 weeks administered intramuscularly.
Study NCT02102646 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Orchiectomy
Description: Androgen deprivation therapy by bilateral subcapsular orchiectomy
Study NCT02314468 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Negative pressure wound therapy
Description: NPWT changed twice a week.
Study NCT02314468 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Glycerol Preserved Allografts (GPA)
Description: GPA changed every 7 to 10 days.
Study NCT04861103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovenox
Description: Three times a day dosing and measuring Xa peak and trough levels
Study NCT01213160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4547
Description: film coated tablet, PO, twice daily
Study NCT03050255 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical air
Study NCT00524511 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgical skin staples
Description: Standard method to close abdominal surgical wounds
Study NCT00524511 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dermabond
Description: Alternative method (superglue) to close abdominal surgical wounds
Study NCT03910634 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluorouracil
Description: 1.33g/body surface QW1, continuous intravenous infusion for 72 hours, repeated for 4 weeks
Study NCT03910634 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiation therapy
Description: Radiotherapy for 5-6 weeks，50-60Gy
Study NCT03910634 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Intensity modulated radiation therapy
Description: Radiotherapy for 5-6 weeks，50-60Gy
Study NCT03910634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin (AUC 2), QW1, intravenous drip, repeat for 4 weeks
Study NCT03910634 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: carboplatin
Description: Carboplatin (AUC 2), QW1, intravenous drip, repeat for 4 weeks
Study NCT03464734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab and Nanoparticle Albumin-bound Paclitaxel
Description: At study entry, patients will receive 2 cycles of pembrolizumab at the dose of 200 mg, intravenously in 30 min, on day 1 and nab-paclitaxel 125 mg/m2 intravenously in 30-40 min, on day 1 and 8.
Study NCT00579215 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhance Care
Description: EC will receive a decision aid with seven components: social support, anticipatory guidance, adhering to the patient's preference for participation in treatment decision making, a quality decision-making process tutorial, normalization (using a CD program), structured time with oncology professionals to discuss difficult decisions, and values clarification of 3 decisions throughout treatment. Self-report measures will be used for all participants in addition to probes for the taped interviews with EC. The outcome measures are quality decision making and decisional conflict. Two panels (decision making and lung cancer) will review the protocol twice. The plan will include serially screening the appointment roster. The decision aid will be administered during three clinic visits
Study NCT00579215 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Care
Description: As an intentional control, the usual care group will receive standard care related to lung cancer and treatment; they will not receive any oral, written, or recorded information related to decision making. Usual care includes anticipatory guidance related to the disease and treatment (e.g., what to do about treatment side effects, signs of an infection, why a treatment would be changed or stopped) using patient education materials normally used in the MSKCC, TOS, Outpatient Clinic.
Study NCT02472821 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interactive youth educational program
Description: Participation in a community-based face-to-face interactive youth educational program focusing on hearing health (i.e., noise hazards, risk of noise-induced hearing loss, mechanism of injury to the internal ear, and preventive measures)
Study NCT02472821 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet-based educational booster
Description: Visit to an educational Web site focused on hearing health
Study NCT01592734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene glycol with electrolytes
Description: Constipation treatment: 1-4 sachets/day according to the patient age. 1 sachet contains 6.9 g PEG-EL. Treatment period: 4 weeks.~Faecal impaction resolution: 4 sachets as initial dose and increasing 2 sachets a day until resolution or up to 7 days.
Study NCT01592734 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol
Description: Constipation: 0.7 g/kg/day in 2 divided doses for children of less than 20 kg. For children > 20 kg the daily dose was up to PEG 30 g daily. Treatment period: 4 weeks.~Faecal impaction resolution: 1.5 g/kg/day in 2 doses until resolution or up to 6 days.
Study NCT03715114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GV-971
Description: Oral GV-971
Study NCT03715114 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Placebo
Study NCT02992288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neladenoson bialanate (BAY1067197)
Description: 5 mg orally once daily for 20 weeks
Study NCT02992288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neladenoson bialanate (BAY1067197)
Description: 10 mg orally once daily for 20 weeks
Study NCT02992288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neladenoson bialanate (BAY1067197)
Description: 20 mg orally once daily for 20 weeks
Study NCT02992288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neladenoson bialanate (BAY1067197)
Description: 30 mg orally once daily for 20 weeks
Study NCT02992288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neladenoson bialanate (BAY1067197)
Description: 40 mg orally once daily for 20 weeks
Study NCT02992288 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally once daily for 20 weeks
Study NCT03398317 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PICSI
Description: sperm selection using PICSI dish for selecting sperm with lower DNA fragmentation index
Study NCT03398317 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MACS
Description: sperm selection using MACS for selecting sperm with lower DNA fragmentation index
Study NCT03050255 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen (2Liter/min)
Study NCT04636125 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Doxycycline 100 MG Oral Tablet
Description: Patients that are undergoing a single stage revision total shoulder arthroplasty will be enrolled in this study. As is standard of care, routine cultures will be taken from predetermined areas in the shoulder. All patients will be treated with 13 days of oral Doxycycline pending culture results.
Study NCT03576586 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief computerized intervention
Description: Brief computerized intervention (computer game Tetris) plus usual care in the maternity department
Study NCT03576586 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention placebo control
Description: Brief cognitive task plus usual care in the maternity department
Study NCT02856568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT02856568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT02856568 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02856568 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02856568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ricolinostat
Description: Given PO
Study NCT04558125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNKase
Description: Tenecteplase (0.25 mg/kg) supplied by Genentech, Inc. as a sterile, lyophilized powder, diluted with 10mL sterile water.
Study NCT04558125 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo to match supplied by Genentech, Inc. as a sterile, lyophilized powder, diluted with 10mL sterile water.
Study NCT03050255 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen (4Liter/min)
Study NCT04558125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: All participants must also receive standard of care anticoagulation therapy.
Study NCT04558125 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: All participants must also receive standard of care anticoagulation therapy.
Study NCT00430014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atiprimod
Description: Starting Dose of 60 mg/day orally for 14 days of 28 day cycle.
Study NCT01328886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: omalizumab lyophilized 150 mg injection
Study NCT00971243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-513 Lowest Dose and Metformin
Description: MP-513 tablets, once a day and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.
Study NCT00971243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-513 Low Dose and Metformin
Description: MP-513 tablets, once a day and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.
Study NCT00971243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-513 Medium Dose and Metformin
Description: MP-513 tablets, once a day and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.
Study NCT00971243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-513 High Dose and Metformin
Description: MP-513 tablets, once a day and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.
Study NCT00971243 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and Metformin
Description: Placebo tablets once a day, and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.
Study NCT02953860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant with Enzalutamide
Description: 500mg of Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC) and 160mg of Enzalutamide will be given PO daily. Patients will receive a tumor biopsy at the start of treatment and 4 weeks after the start of treatment, with an optional 3rd biopsy at the end treatment.
Study NCT03044925 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote magnetic navigation
Description: Pulmonary vein isolation and other areas ablation guided by remote magnetic navigation
Study NCT03044925 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryoablation
Description: Pulmonary vein isolation and other areas ablation used by cryoballoon
Study NCT02817022 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: developmentally supportive care
Description: DSC components will be strictly emphasized on protected sleep, pain and stress assessment and management, activities of daily living (positioning, feeding and skin care), the healing environment
Study NCT03020654 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual environment with fast moving objects
Description: A beach/park environment with graded moving objects, the individual will complete head and eye exercises.
Study NCT03020654 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual environment with no movement
Description: A beach/park environment with static objects, the individual will complete head and eye exercises.
Study NCT02769559 — intervention group
Intervention type: PROCEDURE
Intervention: Reduction mammaplasty
Description: Surgical removal of excess breast tissue
Study NCT01005459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracaine
Description: Tetracaine 2mg will be combined with Fentanyl 20 mcg and Epinephrine 50 mcg to treat labor pain.
Study NCT01005459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine 2 mg combined with fentanyl 20 mcg and Epinephrine 50 mcg will be used to treat labor pain.
Study NCT03998982 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycyrrhetinic Acid
Description: Compound glycyrrhizin tablets 75 mg three times per day, 1 month
Study NCT03998982 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: HD-DXM (orally at 40 mg daily for 4d)
Study NCT01292486 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectra Optia Apheresis System
Description: In this study, the safety and effectiveness of the new device will be assessed in two ways. First, MNC collections in growth-factor mobilized cancer patients will be evaluated to confirm that the Spectra Optia is able to collect stem cells. Second, following stem-cell collection and transplant, the number of days required for the collected hematopoetic stem cells to engraft/recover will be compared with historical COBE Spectra engraftment/recovery data.
Study NCT00685412 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VGX-3100
Description: DNA plasmid delivered via IM injection + electroporation using CELLECTRA device
Study NCT04172181 — intervention group
Intervention type: PROCEDURE
Intervention: cord blood stem cell transplantation
Description: Unrelated cord blood stem cell selection； Reduced intensity conditioning； GVHD prevention； Infection prevention.
Study NCT02264730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ClotFoam
Description: Patient has not received blood products between screenings
Study NCT06052579 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: new hand-held retractor systems-assisted WiltseTLIF surgery
Description: patients were included in study group underwent the new hand-held retractors assisted Wiltse TLIF surgery
Study NCT06052579 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: new hand-held retractor systems-assisted WiltseTLIF surgery
Description: patients were included in study group underwent the new hand-held retractors assisted Wiltse TLIF surgery
Study NCT02835378 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT02496286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraperitoneal Bevacizumab
Description: Bevacizumab 200mg diluted in 250 ml of normal saline
Study NCT02689427 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Axillary Lymph Node Dissection
Description: Undergo axillary lymph node dissection
Study NCT02689427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given PO
Study NCT02689427 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02689427 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymph Node Biopsy
Description: Undergo lymph node biopsy
Study NCT02689427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT02689427 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgical resection of primary tumor
Study NCT01310777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension
Study NCT01310777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brinzolamide 1% ophthalmic suspension
Study NCT01310777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brimonidine tartrate 0.2% ophthalmic solution
Study NCT01452438 — intervention group
Intervention type: BIOLOGICAL
Intervention: MenACWY-CRM
Description: MenACYW-CRM vaccination received as part of routine clinical care and as registered in the vaccine records.
Study NCT03188393 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy of Breast
Description: Undergo stereotactic biopsy
Study NCT02877966 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amixea
Description: Amixea is a mixture of amino acids. It consists mainly of essential amino acids (EAA) that cannot be synthesized de novo by the organism, and therefore must be supplied in its diet.
Study NCT02877966 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01380015 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Commercially spearmint tea
Description: Commercially available, non-selectively bred spearmint tea.
Study NCT02203396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabbit ATG, Cyclosporine, Levamisole
Description: rATG is administered at a dose of 1.97 mg/kg/day for 9 days CSA is administered orally at a dose of 3 mg/kg qod Levamisole is administered orally at a dose of 2.5 mg/kg qod. The CSA and LMS is designed to alternately every other day.
Study NCT01713920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEVIKAR
Study NCT03448796 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HTO
Description: Group that receives high tibial osteotomy combined with supervised physiotherapy as treatment.
Study NCT03448796 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised physiotherapeutic program
Description: Group that receives only supervised physiotherapy as treatment.
Study NCT02485873 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: As prescribed by treating physicians
Study NCT02485873 — intervention group
Intervention type: DRUG
Intervention: Vitamin K antagonists
Description: As prescribed by treating physicians
Study NCT03502005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bictegravir/emtricitabine/tenofovir alafenamide
Description: Discontinue ATRIPLA® and initiate BIKTARVY®
Study NCT04100083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone 50 MG
Description: Study visit timeline: initial visit \[consent and enrollment followed by baseline exam (0 months), 3 months, 6 months, and follow up at 7 months, with optional treatment extension period for up to one year of total treatment during which patients will follow up every 3 months~The drug will be taken via oral tablets once daily for a duration of 6 months. Patients will be instructed to continue any current treatment regimen for hidradenitis suppurativa that was initiated at least 4 weeks prior to their enrollment in the study. Patients will be instructed to avoid potassium supplements and foods containing high levels of potassium, including salt substitutes, which could potentially lead to hyperkalemia. They will be instructed to avoid medications listed in the exclusion criteria.
Study NCT04100083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone 100mg
Description: Study visit timeline: initial visit \[consent and enrollment followed by baseline exam (0 months), 3 months, 6 months, and follow up at 7 months, with optional treatment extension period for up to one year of total treatment during which patients will follow up every 3 months~The drug will be taken via oral tablets once daily for a duration of 6 months. Patients will be instructed to continue any current treatment regimen for hidradenitis suppurativa that was initiated at least 4 weeks prior to their enrollment in the study. Patients will be instructed to avoid potassium supplements and foods containing high levels of potassium, including salt substitutes, which could potentially lead to hyperkalemia. They will be instructed to avoid medications listed in the exclusion criteria.
Study NCT04100083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone 200 mg
Description: Study visit timeline: initial visit \[consent and enrollment followed by baseline exam (0 months), 3 months, 6 months, and follow up at 7 months, with optional treatment extension period for up to one year of total treatment during which patients will follow up every 3 months~The drug will be taken via oral tablets once daily for a duration of 6 months. Patients will be instructed to continue any current treatment regimen for hidradenitis suppurativa that was initiated at least 4 weeks prior to their enrollment in the study. Patients will be instructed to avoid potassium supplements and foods containing high levels of potassium, including salt substitutes, which could potentially lead to hyperkalemia. They will be instructed to avoid medications listed in the exclusion criteria.